symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
IMRX,6.04,-1.035964,50926,176754560,0,3.7-14.29,0.02,Immuneering Corporation,USD,0001790340,US45254E1073,45254E107,NASDAQ Global Market,NASDAQ,Biotechnology,https://immuneering.com,"Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.","Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.",Healthcare,US,66,617 500 8080,245 Main Street,Cambridge,MA,02142,,0,https://financialmodelingprep.com/image-stock/IMRX.png,2021-07-30,False,False,True,False,False
